A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
SynAct Pharma Aps
Why this is shown: Actively enrolling · PHASE2 · 3 sites in FL, PA